Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - hiv infekcie - antivirotiká na systémové použitie - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcíny - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - viacnásobný myelóm - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - viacnásobný myelóm - antineoplastické činidlá - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulárna blokáda - všetky ostatné terapeutické produkty - zvrat neuromuskulárnej blokády indukovanej rokurónom alebo vekuróniom. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplasms, kastrácia-odolný - antineoplastické činidlá - treatment of adult patients with prostate cancer.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinúria, paroxysmálna - imunosupresíva - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). dôkazy z klinických výhodou je preukázaná u pacientov s haemolysis s klinický príznak(s) svedčí o vysokej aktivity ochorenia, bez ohľadu na transfúziu históriu (pozri časť 5.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - viacnásobný myelóm - antineoplastické činidlá - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.